Having completed a successful Seed investment fundraise in 2024 Llusern has its sights set on a £4m Series A raise in 2025. The investment will be used to expand the company’s international market access and fund an innovative pipeline of molecular products.
Dr Emma Hayhurst launched the campaign at OBN’s BioSeed at London’s County Hall that brought together 42 companies all looking for funding from the assembled investors.
Later the same week Llusern pitched at MediWales’ BioWales event held at Future Space on the University of the West of England’s campus in Bristol.
The Executive Team at Llusern wishes to thank OBN and MediWales for organising these invaluable opportunities. Diolch pawb.
The Lodestar DX analyser and testing system is registered with the European Patent Office (European Patent Application no: 22732302.9) and the US Patent and Trademark Office (no.18/558,490).